Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $47,305.50 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Angelita Rebamontan Domingo sold 2,585 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $18.30, for a total value of $47,305.50. Following the completion of the sale, the director now owns 8,191 shares in the company, valued at $149,895.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pro-Dex Trading Up 1.6 %

Shares of NASDAQ PDEX traded up $0.29 during midday trading on Wednesday, hitting $18.89. The company’s stock had a trading volume of 1,595 shares, compared to its average volume of 7,600. The company has a current ratio of 3.45, a quick ratio of 2.08 and a debt-to-equity ratio of 0.25. The business’s 50 day moving average is $19.06 and its two-hundred day moving average is $18.64. Pro-Dex, Inc. has a 12-month low of $14.51 and a 12-month high of $22.99. The firm has a market cap of $64.60 million, a P/E ratio of 32.12 and a beta of 0.41.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.19 earnings per share for the quarter. The firm had revenue of $14.29 million for the quarter. Pro-Dex had a return on equity of 6.50% and a net margin of 4.13%.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 5th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pro-Dex stock. Perritt Capital Management Inc. boosted its position in shares of Pro-Dex, Inc. (NASDAQ:PDEX) by 43.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,000 shares of the medical instruments supplier’s stock after purchasing an additional 1,813 shares during the quarter. Perritt Capital Management Inc. owned about 0.18% of Pro-Dex worth $106,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.